Medical Health & Life Science Research News

Recent research: Global down syndrome pipeline therapeutics market review H2 2017

Learn details of Down Syndrome Pipeline therapeutics Review H2 2016. The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources. The report reviews key players involved Down Syndrome therapeutics drug development and enlists all their major and minor projects

- Agency -.

Down Syndrome Pipeline Review H2 2017 provides an overview of the Down syndrome (Genetic Disorders) pipeline landscape. Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems.

Down syndrome varies in severity, so developmental problems range from moderate to serious. Pharmaceutical and Healthcare latest pipeline guide Down Syndrome Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

- Agency -.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Down syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down syndrome and features dormant and discontinued projects.

Down Syndrome Companies Involved in Therapeutics Development AC Immune SA, Aelis Farma SAS, Eisai Co Ltd, ManRos Therapeutics, NeuroNascent Inc, OPKO Health Inc.

Get this report at www.reportsnreports.com/contacts/discount.aspx?name=1125835 .

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 6, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 2 molecules, respectively.

Down syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access This Down syndrome pipeline report at www.reportsnreports.com/purchase.aspx?name=1125835 .

Down syndrome Drug Profiles discussed in report ACI-24, ALZ-801, D-217, donepezil hydrochloride, Dosmir, ELND-005, minocycline hydrochloride, NNI-351, NNI-362, pentylenetetrazol, Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrom, Small Molecule to inhibit DYRK1A for Alzheimer's and Down Syndrome, small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome, Small Molecules for Down Syndrome, Small Molecules to Inhibit Dyrk1a for Alzheimer's Disease and Down syndrome, Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome, Small Molecules to Inhibit OLIG2 for Down Syndrome, Stem Cell Therapy to Activate.

List of Table:

  1. Number of Products under Development for Down Syndrome, H2 2017
  2. Number of Products under Development by Companies, H2 2017
  3. Number of Products under Development by Universities/Institutes, H2 2017
  4. Products under Development by Companies, H2 2017
  5. Products under Development by Universities/Institutes, H2 2017
  6. Number of Products by Stage and Target, H2 2017
  7. Number of Products by Stage and Mechanism of Action, H2 2017
  8. Number of Products by Stage and Route of Administration, H2 2017
  9. Number of Products by Stage and Molecule Type, H2 2017
  10. Down Syndrome - Pipeline by AC Immune SA, H2 2017
  11. Down Syndrome - Pipeline by Aelis Farma SAS, H2 2017
  12. Down Syndrome - Pipeline by Eisai Co Ltd, H2 2017
  13. Down Syndrome - Pipeline by ManRos Therapeutics, H2 2017
  14. Down Syndrome - Pipeline by NeuroNascent Inc, H2 2017
  15. Down Syndrome - Pipeline by OPKO Health Inc, H2 2017
  16. Down Syndrome - Dormant Projects, H2 2017
  17. Down syndrome - Discontinued Products, H2 2017.

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany profile: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.